Clinical Trial Update: A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Cediranib in combination with Olaparib in advanced solid tumors has posted results as of 2024-07-30. Indications covered include non-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Non-small Cell Lung Cancer
• Pancreatic Adenocarcinoma
• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma
• Small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Cediranib (Cediranib)
• Lynparza (olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-07-30